Make a difference when every minute counts.
In the case of suspected AMI, prompt treatment is essential. Every 30 minutes of delay between symptoms and treatment increases the 1-year mortality rate by 7.5%.4
Troponin is the preferred biomarker in defining AMI according to the European Society of Cardiology (ESC) guidelines.5 In addition, it is the gold standard to distinguish between AMI and non-AMI patients.5,6
Roche Elecsys cardiac Troponin T-high sensitive (TnT-hs) can reduce the time needed to rule-in or rule-out NSTEMI to as little as just 1 hour.1-3